Help
Login
Busy
Search
eHDSI - Issues

 
Select object
 
false
Results (1 / 1)
Id Issue Status Priority Type Date Assigned To Label
285 Add description to epsos:asContent/epsos:name element Closed Low Change Request 2019-04-30 14:30:18 Mathias Ghys
 
 TBA 
 
Change Request Add description to epsos:asContent/epsos:name element
Id epsos-issue-285
Status Closed
Priority Low
Last Tracking 2019-04-30 14:30:18  by  Mathias Ghys
Current Assignee Mathias Ghys
Current Labels
    
 (TBA) To be approved 
    
Concerns
Template
false
epSOS CDA ManufacturedProduct (Medicine Content Entry Module)
/
/
Template 1.3.6.1.4.1.12559.11.10.1.3.1.3.1 (2013-12-20) epSOS CDA ManufacturedProduct
Status Retired
/
-
/
-
Events
Tracking Closed 2019-04-30 14:30:18 : Tracking by Mathias Ghys
    
 TBA 
Description
Descriptions approved during eP cluster meeting and added to the CDA IGs
Assignment 2018-08-20 10:30:42 : Assigned To Mathias Ghys by Mathias Ghys
    
 TBA 
Tracking Open 2018-08-20 10:30:41 : Tracking by Mathias Ghys
    
 TBA 
Description
Finding:

- Since the "asContent" part is a CDA-extension based on IHE Pharmacy profiles, we would suggest to add the description of the IHE Pharmacy profiles to the CDA IGs. This question was raised in the cda-document channel in slack. And by adding a description, it'll be only more clear for other people in the future.

Contents in the IHE Pharmacy profile:

"In case the package describes a product, and the package has a brand name, it SHOULD be described in the <pharm:name> element (e.g., Xylocaine 1% with Adrenaline Inj, 5 injections package)."

According to Marta it is very uncommon that a package has a brand name, but in certain cases it could be the case (she mentioned the example of "Turbohaler").


Suggestion:

-

Further explanation:

-

    
Labels
Preview Code HTML color Display Name Description
 
 TBA 
TBA TBA To be approved
To be discussed and approved
 
 M1 
M1 M1 Milestone 1
Milestone 1 – before the EXPAND-athon 9-12 December 2015 Lisbon
 
 M2 
M2 M2 Milestone 2
Milestone 2 – final results to be delived at the end of EXPAND
 
 M3 
M3 M3 Milestone 3
Milestone 3 – end of the HL7 International Project
 
 M4 
M4 M4 Milestone 4
Milestone 4 – for consideration in the future / desiderata
 
 WJ 
WJ WJ Changes Word/JIRA
Changes in the Word Specification/Open a JIRA issue
 
 TID 
TID TID Template ID
Template-ID changes throughout the specification